Photo of Nizar M. Tanner taken from mdanderson.org
Aug 7, 2024, 03:03
Extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
Daniel Castellano, Medical Oncologist at University Hospital October 12, shared on X:
“Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial – Annals of Oncology.”
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
Autors: N.M. Tannir, L. Albigès, D.F. McDermott, M. Burotto, T.K. Choueiri, H.J. Hammers, P. Barthélémy, E.R. Plimack, C. Porta, S. George, F. Donskov, M.B. Atkins, H. Gurney, C.K. Kollmannsberger, M.-O. Grimm, C. Barrios, Y. Tomita, D. Castellano, V. Grünwald, B.I. Rini, R. Jiang, H. Desilva, V. Federov, C.-W. Lee, R.J. Motzer
Source: Daniel Castellano/X
B.I. Rini
C. Barrios
C. Porta
C.-W. Lee
C.K. Kollmannsberger
cancer
D. Castellano
D.F. McDermott
Daniel Castellano
E.R. Plimack
F. Donskov
H. Desilva
H. Gurney
H.J. Hammers
L. Albigès
M. Burotto
M.-O. Grimm
M.B. Atkins
nivolumab
Nizar M. Tannir
OncoDaily
Oncology
P. Barthélémy
R. J. Motzer
R. Jiang
S. George
T. K. Choueiri
V. Federov
V. Grünwald
Y. Tomita